FDA Proposes Clinical Data Disclosure; Argues Sharing Will Improve Trial Design

The agency suggests making masked clinical trial data available to outside parties for further analysis, saying access may enable researchers to overcome drug development hurdles, such as identification of primary endpoints or potential biomarkers.